LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Vinorelbine 25 mg/m2 weekly|DRUG: Afatinib 40mg once daily (OD)|DRUG: Paclitaxel 80 mg/m2 weekly
Sponsor: Boehringer Ingelheim